Deucravacitinib (BMS-986165) for Pityriasis Rubra Pilaris | MicrobiomeTrials← Back to trialsNCT06444399
Deucravacitinib (BMS-986165) for Pityriasis Rubra Pilaris
CompletedPHASE2INTERVENTIONAL
Trial Details
Start: 2024-07-29Est. Completion: 2025-09-02
Enrollment target: 7 participants Locations- Mayo Clinic in Arizona, Scottsdale, Arizona, United States
Other microbiome trials you might be interested in
Pityriasis Rubra Pilaris
The purpose of this study is to valuate the clinical efficacy of Bimzelx therapy in adults with Pityriasis Rubra Pilaris…
Jacksonville, United StatesEst. completion Aug 1, 2027
Pityriasis Rubra Pilaris
15 patients with PRP will be treated with guselkumab for 20 weeks to determine safety and efficacy. Participants are req…
Portland, United StatesCompleted Aug 11, 2022